---
figid: PMC8877616__jcm-11-00955-g001
figtitle: Current and Emerging Medical Therapies in Pituitary Tumors
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Danio rerio
- Canis lupus familiaris
pmcid: PMC8877616
filename: jcm-11-00955-g001.jpg
figlink: /pmc/articles/PMC8877616/figure/jcm-11-00955-f001/
number: F1
caption: Schematic representation of the main molecular mechanism by which medical
  therapies (DA and other) act in prolactinoma and signaling pathway involved in the
  response to dopamine agonist therapy or medical treatment in prolactin-secreting
  pituitary tumor. For the sake of clarity, major signaling pathways are simplified,
  and readers can refer to the manuscript for more details. On the right side of the
  cell, optional therapies and the ones that are in development are represented. The
  question mark means a possible effect supported by in vitro experiments.
papertitle: Current and Emerging Medical Therapies in Pituitary Tumors.
reftext: Nicolas Sahakian, et al. J Clin Med. 2022 Feb;11(4):955.
year: '2022'
doi: 10.3390/jcm11040955
journal_title: Journal of Clinical Medicine
journal_nlm_ta: J Clin Med
publisher_name: MDPI
keywords: pituitary tumors | acromegaly | cushingâ€™s disease | prolactinoma | dopamine
  agonist | somatostatin
automl_pathway: 0.962933
figid_alias: PMC8877616__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Canis lupus familiaris
- Danio rerio
redirect_from: /figures/PMC8877616__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8877616__jcm-11-00955-g001.html
  '@type': Dataset
  description: Schematic representation of the main molecular mechanism by which medical
    therapies (DA and other) act in prolactinoma and signaling pathway involved in
    the response to dopamine agonist therapy or medical treatment in prolactin-secreting
    pituitary tumor. For the sake of clarity, major signaling pathways are simplified,
    and readers can refer to the manuscript for more details. On the right side of
    the cell, optional therapies and the ones that are in development are represented.
    The question mark means a possible effect supported by in vitro experiments.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFBI
  - TGFBR2
  - SMAD3
  - SMAD2
  - SMAD4
  - DRD2
  - PRL
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - MTOR
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - AKT1
  - AKT2
  - AKT3
  - SSTR5
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CORT
  - SSTR2
  - EGFR
  - Tgfbi
  - Tgfbr2
  - Smad3
  - Smad2
  - Smad4
  - Drd2
  - Prl
  - Creb1
  - Mtor
  - Akt1
  - Sstr5
  - Ephb2
  - Mapk1
  - Pik3r1
  - Sstr2
  - Egfr
  - Ephb1
  - Pik3cg
  - tgfbi
  - tgfbr2b
  - smad3a
  - smad2
  - smad4a
  - smad4b
  - prl
  - mtor
  - sst5
  - sst2
  - egfra
---
